Gilead and Verily collaborate to map three common immune disease molecular maps
May 02, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, Gilead Sciences and Alphabet subsidiary Verily Life Sciences announced that they will use Verily's Immunoscape platform for scientific collaboration to better understand the immunological basis of three common severe inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and lupus Related diseases. The three-year collaboration aims to identify specific subtypes of immune cells to better understand disease characteristics and treatment response, and to guide future drug discovery and development to improve treatment outcomes in patient populations.
Verily is a subsidiary of Alphabet launched in 2015, focusing on life sciences and healthcare. Its mission is to make the world's health data useful and to enable people to enjoy a healthier life. Verily develops tools and devices to collect, organize, and activate health data and create interventions to prevent and manage disease. Its state-of-the-art Immunoscape platform combines immunogenic phenotypes with advanced computational analysis techniques to characterize the molecular characteristics of inflammatory diseases with high resolution.
Through this collaboration, Gilead will provide clinical data and a large number of immune cell samples from pre- and post-medication samples from Phase 2 and Phase 3 clinical trial participants. Verily will use the Immunoscape platform to analyze patient data from Gilead to generate immune data and insights. .
These efforts may bring important new insights into understanding these inflammatory diseases, including identifying molecular features and helping doctors select treatments or doses for specific subgroups of patients to improve treatment outcomes and avoid side effects. The data generated in this collaboration can also better characterize subtypes of inflammatory diseases and help scientists identify new molecular targets that can lead to new therapies.
â–²Verily's ongoing precision medical cooperation (Source: Verily official website)
“Inflammatory diseases are complex and heterogeneous, and although progress has been made, most patients have not achieved deep and lasting relief,†said Dr. John McHutchison, Chief Scientific Officer and Head of Research and Development at Gilead. “We are very happy to be with Verily's scientists work together to accelerate our understanding of these common and serious inflammatory diseases. We hope to use this cutting-edge technology to identify molecular disease pathways that would otherwise be undetected and ultimately improve patient outcomes."
“Using the Immunoscape platform, we are looking to develop a molecular map of inflammatory diseases that will help us identify and characterize disease mechanisms,†added Verily Chief Medical Officer Dr. Jessica Mega. “This collaboration with Gilead is a A rare opportunity to learn more about these immune-mediated diseases than ever before, and to delve into possible pathways to provide patients with more accurate drugs."
Reference materials:
[1] Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
[2] Gilead and Verily Team to Tackle Three Inflammatory Diseases
Temporary Flood Boxwalls,Temporary Flood Barrier,Quick Flood Barrier,Flood Barrier Door
Denilco Environmental technology(Suzhou)Co., Ltd. , https://www.wflood.com